Amryt Pharma plc (AMYT) reported Q2 EPS of ($0.02), $0.02 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $68.5 million versus the consensus estimate of $64.21 million.
GUIDANCE:
Amryt Pharma plc sees FY2022 revenue of $260-270 million, versus the consensus of $269 million.